Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-glutamine is a naturally occurring amino acid and small molecule being investigated as a metabolic therapeutic in the treatment of advanced pancreatic cancer. In the Phase I GlutaPanc trial led by Dr. Jun Gong at Cedars-Sinai Medical Center, L-glutamine is used as an oral supplement in combination with gemcitabine and nab-paclitaxel. Preclinical evidence suggests that glutamine supplementation can enhance the antitumor activity of gemcitabine against pancreatic ductal adenocarcinoma (PDAC) cells, contrary to the traditional approach of glutamine deprivation. The trial aims to establish the safety and recommended Phase II dose of this combination in treatment-naïve patients with locally advanced or metastatic disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on l-glutamine.